

Acute Ischemic Stroke Thrombolysis

## Tenecteplase in Stroke Patients Between 4 and 24 Hours

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

**Trial Status**  
Completed

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT03785678 ML40787

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the efficacy and safety of tenecteplase compared with placebo in participants with acute ischemic stroke (AIS). All participants will receive standard-of-care therapy according to AmericanHeart Association/American Stroke Association clinical guidelines (2018). To determine eligibility for randomization, all participants will undergo multimodal CT or MRI at baseline. Only participants with a vessel occlusion (ICA or MCA M1/M2) and penumbral tissue will be randomized. The primary analysis is to compare the efficacy of tenecteplase versus placebo in all participants at Day 90.

**Genentech, Inc.**  
Sponsor

**Phase 3**  
Phase

---

**NCT03785678 ML40787**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---